Preclinical Cancer Testing
Preclinical Cancer Testing - Related Videos
06:51
A Preclinical Murine Model of Hepatic Metastases
0 Views •
Cited by 119 •
2014
A preclinical, murine model of hepatic metastases performed via a hemispleen injection technique.
07:31
Testing the Vascular Invasive Ability of Cancer Cells in Zebrafish (Danio Rerio)
0 Views •
Cited by 19 •
2016
This method utilizes zebrafish embryos to efficiently test the vascular invasive ability of cancer cells. Fluorescent cancer cells are injected into the precardiac sinus or yolk sac of developing embryos. Cancer cell vascular invasion and extravasation is assessed via fluorescence microscopy of the tail region 24 to 96 hr later.
09:34
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
0 Views •
Cited by 4 •
2021
Rapid and efficient quantification of intracellular M. tuberculosis growth is crucial for pursuing improved therapies against tuberculosis (TB). This protocol describes a broth-based colorimetric detection assay using an automated liquid culture system to quantify Mtb growth in macrophages treated with candidate host-directed therapies.
07:45
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
0 Views •
Cited by 15 •
2020
Patient-derived xenograft (PDX) models and transplantable genetically engineered mouse models faithfully recapitulate human disease and are preferred models for basic and translational breast cancer research. Here, a method is described to orthotopically transplant breast tumor fragments into the mammary fat pad to study tumor biology and evaluate drug response.
09:58
Robotic Production of Cancer Cell Spheroids with an Aqueous Two-phase System for Drug Testing
0 Views •
Cited by 37 •
2015
A protocol for robotic printing of cancer cell spheroids in a high throughput 96-well plate format using an aqueous two-phase system is presented.
FAQs
These models answer different parts of the same scientific question. Cultured tumor cells allow controlled assessment of biological activity and drug response, whereas tumor-bearing animals extend evaluation to tumor growth, surrounding tissues, pharmacokinetics, and toxicity. Comparing both sources helps researchers determine whether an observed effect remains meaningful in a more complex biological setting.
Measuring molecular effects shows more than whether a tumor becomes smaller. These changes help clarify how a treatment acts on cancer cells and surrounding tissues, while tumor-growth measurements indicate the resulting physical response. Using both kinds of evidence can connect a therapy’s biological activity with its observable outcome and expose cases in which those measures do not align.
Controlled variation of dose and treatment combinations helps identify conditions associated with stronger or weaker responses. Researchers can compare potential doses and combinations while also examining toxicity, rather than judging activity in isolation. This information supports selection of regimens for further development and can reveal whether a proposed combination offers a rationale for continued study.
Results from models require cautious interpretation because activity before clinical testing does not guarantee patient benefit. Preclinical cancer testing can reveal risks and limitations early, but model findings remain evidence for deciding whether development is justified, not proof of effectiveness in people. Recognizing this boundary helps researchers avoid overstating laboratory or animal results.
A preclinical workflow links treatment exposure with several outcome measures. Researchers evaluate drug response and molecular effects in laboratory models, then examine tumor growth, pharmacokinetics, and toxicity in tumor-bearing animals when those models are used. The resulting evidence is considered together to judge biological activity, potential risks, dose choices, and readiness for clinical development.
Pharmacokinetic measurements add information about how a treatment behaves during testing, while toxicity assessments identify harmful effects. Considering these findings alongside tumor response helps researchers weigh potential benefit against risk and select more informed dose options. This combined assessment is important because strong biological activity alone may not justify advancing a therapy.
These studies inform clinical trial design by clarifying expected biological effects, candidate doses, treatment combinations, and possible risks before people are enrolled. They may also reveal limitations that shape trial planning. In this way, preclinical evidence supports more focused development decisions without eliminating the uncertainty that accompanies translation from models to patients.